Outcome MeasureOther

SCL-90-R

Symptom Checklist-90-Revised

4 Papers in Blossom

Clinical Thresholds

04
Non-clinical
Score 0–0
At-risk
Score 1–1
Clinical
Score 2–4

Outcome Data Across Studies

Reported results for SCL-90-R across 2 studies with quantitative data.

Outcome data across 7 study arm–timepoint observations
SD
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Secondary
Full dose LSD(experimental)0869.66.7—
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Secondary
Full dose LSD(experimental)60860.27.2—
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Secondary
Active placebo LSD(active_comparator)0366.015.1—
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Secondary
Active placebo LSD(active_comparator)60367.710.2—
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases
2014Secondary
Active placebo LSD(active_comparator)60357.315.0—
Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study
2023Secondary
LSD(experimental)0201.10.6—
Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study
2023Secondary
Placebo(inactive)0221.30.7—

Papers Using SCL-90-R

Open Accessindividual

Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial

This double-blind controlled trial (n=61) found that high-dose LSD-assisted therapy (100μg + 200μg) reduced depression symptoms more than low-dose LSD (25μg + 25μg) in patients with moderate-to-severe major depressive disorder (MDD), with benefits lasting up to 12 weeks and similar side effects between groups.

Published
Journal
Med
Authors
Mu, F., Zaczek, H., Becker, A. M., Auernig, M., Boehlke, C., Liechti, M. E., Ley, L., Borgwardt, S., Santos De Jesus, J., Loh, N., Kohut, J.
Open Accessindividual

Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations

In controlled semi‑structured dyadic conversations, both MDMA (100 mg) and methamphetamine (20 mg) increased participants' feelings of connectedness relative to placebo. Both drugs elevated oxytocin, but only MDMA's oxytocin increase correlated with subjective closeness, indicating similar behavioural effects may arise from different neuroendocrine mechanisms and demonstrating a sensitive method for measuring pro‑social drug effects in person.

Published
Journal
Scientific Reports
Authors
Molla, H. M., Lee, R., Lyubomirsky, S., de Wit, H.
Open Accessindividual

Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study

This double-blind cross-over trial (n=42) finds that LSD (2x 200 μg) significantly reduced anxiety (STAI-G) scores up to three months after treatment. The patients, both with and without a life-threatening illness, also improved on measures of depression (HAM-D, BDI). Those with more subjective drug effects and mystical-type experiences had better outcomes.

Published
Journal
Biological Psychiatry
Authors
Holze, F., Gasser, P., Müller, F., Dolder, P. C., Liechti, M. E.
Open Accessindividual

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

This double-blind cross-over study (n=12) showed that LSD (200 μg, 2 sessions) in combination with psychotherapy was safe to use and trended towards a positive effect on end-of-life anxiety.

Published
Journal
Journal of Nervous and Mental Disease
Authors
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., Brenneisen, R.

Quick Facts

Full Name
Symptom Checklist-90-Revised
Domain
Other
Papers Indexed
4
Score Range
0–4
Interpretation
Lower = better
Unit
points (GSI)
All Measures